ECCMID 26th (2016)

Drupal spam blocked by CleanTalk.
Title Content type
Candida bloodstream infections in a general hospital of Southwestern Greece during a five-year period (click for details)
In vitro anti-Candida activity of a Spirulina platensis extract: a new approach for the treatment of fungal infections? (click for details)
Therapeutic drug monitoring of antifungal drugs: another tool to improve patients outcome? (click for details)
Molecular analysis by DiversiLab and antifungal susceptibility by YeastOne of clinical isolates of Trichosporon asahii from Turkey (click for details)
Candida bloodstream infections in a Greek tertiary hospital: 5-year survey – epidemiology and in vitro antifungal susceptibility profiles (click for details)
Utility of the IA diagnosis biomarker bis(methylthio)gliotoxin to monitor voriconazole treatment (click for details)
Is fluconazole resistance (FLU-R) in Cryptococcus neoformans predictive of clinical outcome? (click for details)
Evaluation of the Sensititre YeastOne colorimetric antifungal panel for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin, adopting the new CLSI clinical breakpoints and epidemiological cutoff values (click for details)
EDTA inhibits Rhizopus oryzae (Rhizopus arrhizus) growth in vitro in blood of diabetic and non-diabetic individuals - is it an option for combined therapy with antifungal agents in the future? (click for details)
Factors correlated to the length of antifungal therapy in a cohort of patients with candidaemia (click for details)

Pages

Subscribe to ECCMID 26th (2016)